Enrolling by invitation

Glycemic Screening Outreach for Prediabetes and Type 2 Diabetes

What is being tested

Text message

+ Patient portal message

+ Mailed letter

Behavioral

Who is being recruted

Body Weight+5

+ Nutrition Disorders

+ Nutritional and Metabolic Diseases

From 35 to 70 Years

+2 Eligibility Criteria

See all eligibility criteria

How is the trial designed

Screening Study

Interventional

Study Start: July 2025

See protocol details

Summary

Principal SponsorUniversity of California, Los Angeles

Last updated: January 28, 2026

Sourced from a government-validated database.Claim as a partner

Study start date: July 8, 2025

Actual date on which the first participant was enrolled.

This study focuses on improving the screening process for people at risk of prediabetes or type 2 diabetes (T2D). With about 130 million Americans potentially affected, many remain undiagnosed because they haven't been screened. While national guidelines recommend screening, few studies have looked into how to effectively encourage more people to get screened. The study aims to test new strategies that could encourage more patients to undergo glycemic screening, helping them detect prediabetes or T2D earlier. This is important because early detection can lead to better management and treatment options, such as lifestyle changes or medical interventions. Participants in this study will be part of a trial called SMART, which stands for Sequential Multiple Assignment Randomized Trial. The trial will explore different approaches to promoting glycemic screening among adults who are at risk. The study will assess how feasible and acceptable these strategies are, which means it will look at how easy they are to implement and how well they are received by patients. The results will help design a larger trial in the future that could improve the way screenings are conducted in health systems, ultimately benefiting many people by facilitating earlier diagnosis and treatment of diabetes.

Official TitleSMART Pilot Trial of Glycemic Screening Outreach

NCT06915194

Principal SponsorUniversity of California, Los Angeles

Last updated: January 28, 2026

Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

105 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Screening Study

Screening studies test new methods to find diseases or risk factors early—before any symptoms appear. This helps catch health issues sooner, when they may be easier to treat.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.

Conditions

Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 35 to 70 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Body WeightNutrition DisordersNutritional and Metabolic DiseasesObesitySigns and SymptomsPathological Conditions, Signs and SymptomsOvernutritionOverweight

Criteria

1 inclusion criteria required to participate

Overweight or obese

1 exclusion criteria prevent from participating

Existing type 2 diabetes, A1c drawn within past 3 years

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.

Treatment Groups

Study Objectives

4 intervention groups are designated in this study

This study does not include a placebo group

Treatment Groups

Group I

Experimental

Participants are initially randomized to glycemic screening invitations by patient portal, and then if they are not screened within 30 days, then they are re-rerandomized to another glycemic screening invitation by text. If they are still not screened in another 30 days then they receive a mailed letter encouraging glycemic screening.

Group II

Experimental

Participants are initially randomized to glycemic screening invitations by text, and then if they are not screened within 30 days, then they are re-rerandomized to another glycemic screening invitation by patient portal. If they are still not screened in another 30 days then they receive a mailed letter encouraging glycemic screening.

Group III

Experimental

Participants are initially randomized to glycemic screening invitations by text, and then if they are not screened within 30 days, then they are re-rerandomized to another glycemic screening invitation by text. If they are still not screened in another 30 days then they receive a mailed letter encouraging glycemic screening.

Group IV

Experimental

Participants are initially randomized to glycemic screening invitations by patient portal, and then if they are not screened within 30 days, then they are re-rerandomized to another glycemic screening invitation by patient portal. If they are still not screened in another 30 days then they receive a mailed letter encouraging glycemic screening.

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

University of California, Los Angeles

Los Angeles, United StatesOpen University of California, Los Angeles in Google Maps

Enrolling by invitationOne Study Center